BIOMARIN PHARMACEUTICAL INC Insider Trading Activity
Every SEC Form 4 insider transaction reported for BIOMARIN PHARMACEUTICAL INC (BMRN), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are BMRN insiders buying or selling?
In the last 12 months, BIOMARIN PHARMACEUTICAL INC insiders reported 0 open-market purchases ($0) and 5 sales ($4.3M) — net selling of $4.3M. Since January 2018, Trabud has recorded 210 Form 4 filings for BMRN: 2 buys ($1.3M) and 208 sells ($178.6M).
Source: SEC EDGAR Form 4
What stands out
- No BIOMARIN PHARMACEUTICAL INC insider made an open-market purchase in the last 12 months; the 5 reported open-market sales totaled $4.3M.
Key Statistics (January 2018 – Sep 3, 2026)
Total Form 4 filings
210
SEC EDGAR
Insider filers
20
Insider buys (2)
$1.3M
Insider sells (208)
$178.6M
Insider sentiment
Net sellingNet insider flow of $177.3M in net selling since January 2018, and $4.3M in net selling over the last 12 months.
Recent BMRN insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | George Eric Davis | EVP, Chief Legal Officer | Sale | 17.6K | $66.28 | $1.2M | SEC ↗ |
| May 11, 2026 | Gregory R Friberg | EVP, Chief R&D Officer | Sale | 3.3K | $53.85 | $176.7K | SEC ↗ |
| Mar 12, 2026 | Charles Greg Guyer | EVP, Chief Technical Officer | Sale | 16.5K | $60.46 | $996.7K | SEC ↗ |
| Feb 27, 2026 | Gregory R Friberg | EVP, Chief R&D Officer | Sale | 6.3K | $60.38 | $381.9K | SEC ↗ |
| Feb 27, 2026 | George Eric Davis | EVP, Chief Legal Officer | Sale | 26.1K | $61.36 | $1.6M | SEC ↗ |
| May 20, 2025 | Erin Burkhart | GVP, Chief Accounting Officer | Sale | 1.8K | $59.31 | $105.9K | SEC ↗ |
| May 6, 2025 | Cristin Hubbard | EVP, Chief Commercial Officer | Sale | 273 | $64.92 | $17.7K | SEC ↗ |
| Mar 20, 2025 | Erin Burkhart | GVP, Chief Accounting Officer | Sale | 1.3K | $71.52 | $92.6K | SEC ↗ |
| Mar 7, 2025 | Charles Greg Guyer | EVP, Chief Technical Officer | Sale | 7.0K | $71.28 | $501.4K | SEC ↗ |
| Feb 26, 2025 | Erin Burkhart | GVP, Chief Accounting Officer | Sale | 1.3K | $68.38 | $91.9K | SEC ↗ |
| Nov 14, 2024 | Charles Greg Guyer | EVP, Chief Technical Officer | Sale | 5.3K | $66.37 | $350.3K | SEC ↗ |
| Aug 15, 2024 | Erin Burkhart | GVP, Chief Accounting Officer | Sale | 714 | $90.00 | $64.3K | SEC ↗ |
| May 31, 2024 | Brian Mueller | EVP, Chief Financial Officer | Sale | 5.0K | $75.19 | $375.9K | SEC ↗ |
| May 30, 2024 | George Eric Davis | EVP, Chief Legal Officer | Sale | 40.9K | $74.51 | $3.0M | SEC ↗ |
| May 13, 2024 | Jean Jacques Bienaime | Director | Sale | 40.0K | $81.38 | $3.3M | SEC ↗ |
| May 6, 2024 | George Eric Davis | EVP, Chief Legal Officer | Sale | 1.9K | $85.01 | $157.3K | SEC ↗ |
| May 6, 2024 | Jeffrey Robert Ajer | EVP, Chief Commercial Officer | Sale | 5.0K | $82.91 | $414.6K | SEC ↗ |
| Apr 15, 2024 | Jean Jacques Bienaime | Director | Sale | 40.0K | $91.13 | $3.6M | SEC ↗ |
| Apr 12, 2024 | Erin Burkhart | GVP, Chief Accounting Officer | Sale | 2.3K | $90.00 | $205.7K | SEC ↗ |
| Mar 7, 2024 | Henry J Fuchs | President, Worldwide R&D | Sale | 35.3K | $85.18 | $3.0M | SEC ↗ |
| Mar 7, 2024 | Jean Jacques Bienaime | Director | Sale | 2.0K | $86.11 | $172.2K | SEC ↗ |
| Mar 7, 2024 | Jeffrey Robert Ajer | EVP, Chief Commercial Officer | Sale | 4.0K | $87.07 | $348.3K | SEC ↗ |
| Feb 29, 2024 | Jean Jacques Bienaime | Director | Sale | 1.0K | $90.35 | $90.3K | SEC ↗ |
| Feb 12, 2024 | Jean Jacques Bienaime | Director | Sale | 30.0K | $89.03 | $2.7M | SEC ↗ |
| Dec 14, 2023 | George Eric Davis | EVP, Chief Legal Officer | Sale | 13.8K | $95.30 | $1.3M | SEC ↗ |
Showing the 25 most recent of 210 Form 4 filings for BIOMARIN PHARMACEUTICAL INC.
Most active BMRN insiders
- Jean Jacques Bienaime82 filings
- Jeffrey Robert Ajer29 filings
- George Eric Davis23 filings
- Bryan V Lawlis16 filings
- Brian Mueller15 filings
Ask anything about BMRN insider activity
Use Trabud's AI agent to query BIOMARIN PHARMACEUTICAL INC's Form 4 history in plain English — "Show me BMRN CEO purchases this year" or compare it against any other ticker.
Open the AI agentBMRN insider trading FAQ
Are BIOMARIN PHARMACEUTICAL INC insiders buying or selling?
In the last 12 months, BIOMARIN PHARMACEUTICAL INC insiders reported 0 open-market purchases ($0) and 5 sales ($4.3M) — net selling of $4.3M. Since January 2018, Trabud has recorded 210 Form 4 filings for BMRN: 2 buys ($1.3M) and 208 sells ($178.6M). Over the full record that is net selling of $177.3M.
How many insiders trade BMRN stock?
20 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for BIOMARIN PHARMACEUTICAL INC. The most recent filing was accepted on Sep 3, 2026.
Where does Trabud get BMRN insider trading data?
All BMRN insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.